Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease

CONCLUSION: Recombinant humanized anti-HER2 monoclonal antibody, administered as a single agent, produces durable objective responses and is well tolerated by women with HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Side effects that are commonly observed with chemotherapy, such as alopecia, mucositis, and neutropenia, are rarely seen.PMID:36881998 | DOI:10.1200/JCO.22.02510

Source: Clinical Genitourinary Cancer - March 7, 2023 Category: Cancer & Oncology Authors: Melody A Cobleigh Charles L Vogel Debu Tripathy Nicholas J Robert Susy Scholl Louis Fehrenbacher Janet M Wolter Virginia Paton Steven Shak Gracie Lieberman Dennis J Slamon Source Type: research